A multicenter post-marketing evaluation of the Elixir DESolve® Novolimus-eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study.

Holger NefJens Wiebe Niklas F Boeder Oliver DörrTimm BauerKarl-Eugen HauptmannAzeem LatibAntonio ColomboDieter FischerTanja RudolphNicolas FoinGert RichardtChristian Hamm

Published in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2018)

Results through 12 months indicate that the DESolve BRS is a safe and effective treatment for coronary lesions, though larger, long-term prospective studies are needed.

Keyphrases

coronary artery
coronary artery disease
heart failure
combination therapy
tissue engineering
left ventricular
case control
aortic valve
smoking cessation